Nick Dragojlovic

Nick Dragojlovic is a health services researcher at the University of British Columbia's Faculty of Pharmaceutical Sciences. He has previously held postdoctoral fellowships at the University of Calgary and at UBC, and has received funding from the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research. He holds a BA from Yale University and an MA and PhD from UBC. Nick is particularly interested in the use of alternative finance mechanisms to support scientific research, and covers the topic on his blog: Funded Science

Posts by: Nick


The race to develop senescent cell clearance therapies

Author: Nick Dragojlovic, 05/03/16

A growing focus of biomedical research and regenerative medicine is the effort to target the aging process itself, by either slowing or reversing the accumulation of cellular and molecular damage that drives age-related functional decline. The goal is to develop new treatments for age-related chronic diseases, which are the leading cause of death in the…Read more

How online outreach adds value to scientific research

Author: Nick Dragojlovic, 03/04/15

> Scientists: I have some questions. Have you ever written a blog post about your field? Tweeted a link to a new scientific publication? Joined a forum discussion about the latest research? As it turns out, your likelihood of answering “yes” to one or more of these questions is no better than a coin flip….Read more

Update on crowdfunding in the regenerative medicine space

Author: Nick Dragojlovic, 05/26/14

> In a recent post on Signals, David Kent made the case for government-funded clinical trials of autologous stem cell therapies, since the lack of proven commercialization models in this area make it difficult to attract private investment. Another way of financing the clinical translation of stem cell therapies with limited commercialization potential is the…Read more

Why clinical translation is key to CIRM’s quest for more funding

Author: Nick Dragojlovic, 12/02/13

> As the expiration of the California Institute for Regenerative Medicine’s (CIRM) funding approaches, the fate of CIRM after 2017 is top of mind for stem cell researchers in the state. While the agency’s leadership appears to be leaning towards some form of public-private partnership, planning for its financial future has reportedly assumed the future…Read more

Science Idol: Could regenerative medicine R&D be crowdfunded?

Author: Nick Dragojlovic, 07/23/13

Would you use/support crowdfunding for research? Take the survey at the end of this post. . Biomedical research is expensive, and existing sources of funding often fall short. Profitable business models for the development of cell-based therapies are still being worked out, so investment in regenerative medicine start-ups can be difficult to secure. Foundations and…Read more

How does the U.S. public rate the FDA’s performance?

Author: Nick Dragojlovic, 04/23/13

. The U.S. Food and Drug Administration’s (FDA) ongoing efforts to assert its authority to regulate U.S.-based companies that offer unlicensed stem cell therapies (Regenerative Sciences or Celltex, for example) has prompted a mixed response from the regenerative medicine community. On the one hand, getting an unlicensed treatment has many potential downsides, so the FDA’s…Read more

State politics and the stem cell policy environment in the United States

Author: Nick Dragojlovic, 02/20/13

– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is consistent with existing statutes, such as the Dickey-Wicker Amendment. The principal implication of this…Read more

Finding the positive in the hype about stem cells

Author: Nick Dragojlovic, 12/20/12

“Stem Cells Make Aging Mice Young Again” – ABC News  “’Factor X’ — Have we finally found the fountain of youth?” – Fox News  “Stem cells, the secret to eternal youth?” – Euronews.com Headlines like these are all too common and underscore how the news media’s coverage of regenerative medicine tends to focus on the…Read more

The future of the stem cell controversy: Do citizens prefer iPS cells?

Author: Nick Dragojlovic, 11/08/12

If you’ve been feeling like you can’t open a web browser these days without finding a story about induced pluripotent stem cells (iPSCs), you’re not alone.  Unlike embryonic stem cells, iPSCs are created by directly reprogramming adult cells taken from donors or patients, and they’ve been all over the news. Most notably, Sir John B….Read more